{"doi":"10.3389/fnagi.2023.1122300","title":"Clinical antidiabetic medication used in Alzheimer’s disease: From basic discovery to therapeutics development","abstract":"<jats:p>Alzheimer’s disease (AD) is a common neurodegenerative disease. Type 2 diabetes mellitus (T2DM) appears to increase and contributing to the risk of AD. Therefore, there is increasing concern about clinical antidiabetic medication used in AD. Most of them show some potential in basic research, but not in clinical research. So we reviewed the opportunities and challenges faced by some antidiabetic medication used in AD from basic to clinical research. Based on existing research progress, this is still the hope of some patients with special types of AD caused by rising blood glucose or/and insulin resistance.</jats:p>","journal":"Frontiers in Aging Neuroscience","year":2023,"id":652338,"datarank":0.41588830833596724,"base_score":2.772588722239781,"endowment":2.772588722239781,"self_citation_contribution":0.41588830833596724,"citation_network_contribution":0.0,"self_endowment_contribution":0.41588830833596724,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":15,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1575056,"name":"Nanqu Huang","orcid":null,"position":1,"is_corresponding":false},{"id":404170,"name":"Di Cui","orcid":"0000-0001-7069-339X","position":2,"is_corresponding":false},{"id":1231621,"name":"Jingshan Shi","orcid":"0000-0002-2537-1751","position":3,"is_corresponding":false},{"id":1259482,"name":"Yu Qiu","orcid":"0000-0002-2707-3993","position":4,"is_corresponding":false},{"id":928563,"name":"Juan Huang","orcid":"0000-0002-5851-5897","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Clinical antidiabetic medication used in Alzheimer’s disease: From basic discovery to therapeutics development","abstract":"<jats:p>Alzheimer’s disease (AD) is a common neurodegenerative disease. Type 2 diabetes mellitus (T2DM) appears to increase and contributing to the risk of AD. Therefore, there is increasing concern about clinical antidiabetic medication used in AD. Most of them show some potential in basic research, but not in clinical research. So we reviewed the opportunities and challenges faced by some antidiabetic medication used in AD from basic to clinical research. Based on existing research progress, this is still the hope of some patients with special types of AD caused by rising blood glucose or/and insulin resistance.</jats:p>","is_dataset_classified":null,"base_score":2.772588722239781,"endowment":2.772588722239781,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"36845652","pmcid":"PMC9950577","openalex_id":"https://openalex.org/W4319984923","authors":[],"funders":[{"funder_name":"National Natural Science Foundation of China","grant_id":"82060728","title":null}],"total_grants":1,"fwci":1.427,"citation_percentile":0.81383824,"influential_citations":0,"citation_trend":[{"year":2023,"count":1},{"year":2024,"count":3},{"year":2025,"count":8},{"year":2026,"count":3}],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://www.frontiersin.org/articles/10.3389/fnagi.2023.1122300/pdf","host_type":"journal"},{"url":"https://www.frontiersin.org/articles/10.3389/fnagi.2023.1122300/pdf","host_type":"publisher"},{"url":"https://www.frontiersin.org/articles/10.3389/fnagi.2023.1122300/full","host_type":"publisher"},{"url":"https://doi.org/10.3389/fnagi.2023.1122300","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/36845652","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/9950577","host_type":"repository"},{"url":"https://doaj.org/article/1c26cd8917564645b48066f8b6fda915","host_type":"repository"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9950577/pdf/fnagi-15-1122300.pdf","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC9950577","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC9950577?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Neurological Disorders and Treatments","Cholinesterase and Neurodegenerative Diseases","Natural Antidiabetic Agents Studies"],"mesh_terms":[],"keywords":["Drug discovery","Disease","Medicine","Alzheimer's disease","Neuroscience","Pharmacology","Intensive care medicine","Bioinformatics","Internal medicine","Psychology","Biology","Type 2 diabetes mellitus","Alzheimer’s disease","Clinical research","Antidiabetic Medication","Type 3 Diabetes Mellitus (T3dm)"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-10T13:06:15.341696Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}